- treatment for reducing the signs and symptoms and inducing and maintaining clinical remission in adults with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy
reducing the signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab - the only other approved biologic for treatment of Crohn's disease
Crohn's disease (the fourth USFDA approval in immune-mediated diseases for HUMIRA®) is a serious chronic, inflammatory disease of the gastrointestinal (GI) with no medical or surgical cure and only a few options for patients with this chronic condition.
HUMIRA® - the only fully human monoclonal antibody approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) in the U.S. and Europe (in addition to Crohn’s disease in the U.S.) - works by blocking TNF-alpha, a protein that when produced in excess, plays a central role in the inflammatory responses of many immune-mediated diseases.
Find more details from the press release.
